KCM
ACRS icon

Kennedy Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Kennedy Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-74,962
Closed -$2.03M – 732
2017
Q2 		$2.03M Buy
+74,962
New +$2.04M 0.04% 586

Other funds holding ACRS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SMV
Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Kennedy Capital Management's ACRS Position: Q3 2017 in Review

Kennedy Capital Management sold out of Aclaris Therapeutics (ACRS) in Q3 2017, closing a stake of 74,962 shares — an estimated $2.03M sold.

Kennedy Capital Management first reported a position in ACRS in Q2 2017 and held it in 1 quarter. The position peaked at $2.03M in Q2 2017. 104 funds tracked by Wall St. Rank hold ACRS as of Q3 2017.

  • Kennedy Capital Management reported no remaining Aclaris Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Kennedy Capital Management sold 74,962 Aclaris Therapeutics shares in Q3 2017, an estimated $2.03M.
  • Kennedy Capital Management first reported a position in Aclaris Therapeutics in Q2 2017 and held it in 1 quarter.
  • Kennedy Capital Management's Aclaris Therapeutics position peaked at $2.03M in Q2 2017.
  • 104 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2017.

Based on Kennedy Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.